{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T17:28:36Z","timestamp":1648574916971},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[1999,2,1]],"date-time":"1999-02-01T00:00:00Z","timestamp":917827200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Klin"],"published-print":{"date-parts":[[1999,2]]},"DOI":"10.1007\/bf03042032","type":"journal-article","created":{"date-parts":[[2009,5,29]],"date-time":"2009-05-29T02:23:08Z","timestamp":1243563788000},"page":"39-41","source":"Crossref","is-referenced-by-count":1,"title":["Konsequenzen der galenischen Unterschiede und klinischen Studienergebnisse mit Budesonid und 5-Aminosalicylaten f\u00fcr die Therapie des Morbus Crohn"],"prefix":"10.1007","volume":"94","author":[{"given":"Eduard F.","family":"Stange","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03042032_CR1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0016-5085(98)70254-9","volume":"115","author":"S Bar Meir","year":"1998","unstructured":"Bar Meir S, for the Israeli Budesonide Study Group. Budesonide versus prednisone in the treatment of active Crohn\u2019s disease. Gastroenterology 1998;115:835\u201340.","journal-title":"Gastroenterology"},{"key":"BF03042032_CR2","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/gast.1997.v113.pm9352848","volume":"113","author":"C Cam\u00e1","year":"1997","unstructured":"Cam\u00e1 C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn\u2019s disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465\u201373.","journal-title":"Gastroenterology"},{"key":"BF03042032_CR3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","volume":"41","author":"M Campieri","year":"1997","unstructured":"Campieri M, Ferguson A, Doe W, et al., and the Global Budesonid Study Group. Oral budesonide is as effective as oral prednisolone in active Crohn\u2019s disease. Gut 1997;41:209\u201314.","journal-title":"Gut"},{"key":"BF03042032_CR4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2036.1998.00285.x","volume":"12","author":"A Ferguson","year":"1998","unstructured":"Ferguson A, Campieri M, Doe W, et al. Oral budesonide as maintenance therapy in Crohn\u2019s disease \u2014 results of a 12-month study. AL Pharmacol Ther 1998;12:175\u201383.","journal-title":"AL Pharmacol Ther"},{"key":"BF03042032_CR5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","volume":"331","author":"GR Greenberg","year":"1994","unstructured":"Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn\u2019s disease. N Engl J Med 1994;331:836\u201341.","journal-title":"N Engl J Med"},{"key":"BF03042032_CR6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","volume":"110","author":"GR Greenberg","year":"1996","unstructured":"Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn\u2019s disease: a placebo-controlled dose-ranging study. Gastroenterology 1996;110:45\u201351.","journal-title":"Gastroenterology"},{"key":"BF03042032_CR7","first-page":"905","volume":"8","author":"V Gross","year":"1996","unstructured":"Gross V, Andus T, Caesar I, et al. Oral pH modified release budesonide versus 6-methylprednisolone in active Crohn\u2019s disease. Eur J Gastroenterol Hepatol 1996;8:905\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"BF03042032_CR8","first-page":"581","volume":"33","author":"V Gross","year":"1996","unstructured":"Gross V, Andus T, Fischbach W, et al., German 5-ASA-Study Group. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn\u2019s disease. Z Gastroenterol 1996;33:581\u20134.","journal-title":"Z Gastroenterol"},{"key":"BF03042032_CR9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/gut.42.4.493","volume":"42","author":"V Gross","year":"1998","unstructured":"Gross V, Andus T, Ecker KW, et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn\u2019s disease. Gut 1998;42:493\u20136.","journal-title":"Gut"},{"key":"BF03042032_CR10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gut.39.1.82","volume":"39","author":"R L\u00f6fberg","year":"1996","unstructured":"L\u00f6fberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocoecal Crohn\u2019s disease. A placebo controlled one year study. Gut 1996;39:82\u20136.","journal-title":"Gut"},{"key":"BF03042032_CR11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","volume":"331","author":"P Rutgeerts","year":"1994","unstructured":"Rutgeerts P, Loefberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn\u2019s disease. N Engl J Med 1994;331:842\u20135.","journal-title":"N Engl J Med"},{"key":"BF03042032_CR12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0016-5085(93)90337-C","volume":"104","author":"JW Singleton","year":"1993","unstructured":"Singleton JW, Hanauer S, Gitnick GL, et al., Pentasa Crohn\u2019s Disease Study Group. Mesalamine capsules for the treatment of active Crohn\u2019s disease: results of a 16-week trial. Gastroenterology 1993;104:1293\u2013301.","journal-title":"Gastroenterology"},{"key":"BF03042032_CR13","first-page":"541","volume":"35","author":"EF Stange","year":"1997","unstructured":"Stange EF, Schreiber S, Raedler A, et al., f\u00fcr die Konsensuskoferenz. Therapie des Morbus Crohn. Z Gastroenterol 1997;35:541\u201355.","journal-title":"Z Gastroenterol"},{"key":"BF03042032_CR14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJM199808063390603","volume":"339","author":"O Thomsen","year":"1998","unstructured":"Thomsen O, Cortot A, Jewell D, et al. A comparison of budesonide and mesalazine for active Crohn\u2019s disease. N Engl J Med 1998;339:370\u20134.","journal-title":"N Engl J Med"}],"container-title":["Medizinische Klinik"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03042032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03042032\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03042032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T01:17:15Z","timestamp":1558574235000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03042032"}},"subtitle":["Ein Fazit"],"short-title":[],"issued":{"date-parts":[[1999,2]]},"references-count":14,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[1999,2]]}},"alternative-id":["BF03042032"],"URL":"https:\/\/doi.org\/10.1007\/bf03042032","relation":{},"ISSN":["0723-5003","1615-6722"],"issn-type":[{"value":"0723-5003","type":"print"},{"value":"1615-6722","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,2]]}}}